Impruvon has filed a notice of an exempt offering of securities to raise $2,499,995.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Impruvon is raising up to $2,499,995.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Impruvon
Empowering IDD Residential Teams. Elevating Care. At Impruvon Health, we are transforming medication management and clinical workflows with intuitive, one-click solutions that simplify processes, eliminate inefficiencies, and empower care teams to do more with ease and confidence. Designed in partnership with IDD providers, our platform automates medication administration and other clinical workflows such as treatments, minimizes errors, and strengthens complianceensuring safer, more effective care for the individuals who depend on it, while keeping providers aligned with regulatory requirements effortlessly. By enhancing efficiency and oversight, we help organizations reduce risk, improve outcomes, and support their teams in delivering high-quality care with less stress. Because when care teams are set up for success, the individuals they support can thrive. Smarter solutions. Safer medication. Confident care.
To learn more about Impruvon, visit http://impruvonhealth.com/
Impruvon Linkedin Page: https://www.linkedin.com/company/impruvon-health/
Contact:
Justin Amoyal, Chief Executive Officer
410-818-7272
https://www.linkedin.com/in/justin-amoyal/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.